A Randomized, Double‐Blind, Placebo‐Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Results of the Maintenance Period of the TOUCHSTONE Study: 1841. (October 2015) - Hanauer, Stephen B.